DRA 162.

Loughborough University The Centre for Biological Engineering	Acquisition and Receipt of Biological Materials					
Doc Ref: FS008.1 : HTA-PR-FORM/	Version N°:	1.0	Issue Date:			

ARF No: CBE/ARF/000 26

PART A: To be completed by the	e Receiv	er (a separate	form must be	completed for	each sample	type)		
A1. Details of Sample/Specimen								
Type/ID: (eg primary cell, cell line, tissufluid, excreta, biological agent)	ıe, body	Dermal fibroblasts					⊠ Human □ Animal	
Format / Quantity: (eg vials, slides, e	etc)	1x1ml vial						
Tissue site/Organ source:		skin						
Batch N°:		62126525 (atcc)						
Is the sample/specimen consider If No, go to section A2.	ed to b	e Relevant Ma	terial under the	Human Tissue	Act (HTA)?		⊠Yes □No	
Is the material obtained from an	HTA lice	enced Tissue E	ank with REC a	pproval for gen	eric research	use?	⊠Yes □No	
Is the material obtained for stora	age and	use under a p	roject specific N	IHS REC approv	al?		□Yes □No	
Is the material licensable under the HTA? Indicate source below:						⊠Yes □No		
	Commer	cial Supplier	☐ Imported (fro	om outside Eng	land, Wales o	or N.Ireland)	1 cm ²	
If Yes, list lot numbers (or other identifier) & the corresponding assigned unique sample ID						Unique ID (Procuro):		
If Yes, provide Project Ref N°:		TBC						
If Yes, provide the name of the P	l:	Dr Elizabeth Ratcliffe						
A2. Details of Receipt			7					
Date/Time of receipt		Date	June 2016		Time:			
ID of Receiver	•	Name:	J. Ali		Dept:	СВЕ		
ID of Supplier/Provider		Name:	ATCC		Country:	UK		
PART B: To be completed by the	Receiv	er						
B1. Inspection and Quarantine								
Has a biological risk assessment for the use of this material been approved?		□Yes ⊠No	Ref Number:	Ref Number:				
Physical integrity of the material(s) acceptable?		⊠Yes □No	If No, describ	be action taken				
Quantity received correct?		⊠Yes □No	If No, describ	No, describe action taken				
Labelling correct and legible?		⊠Yes □No	If No, describe action taken					
I IC THE PEIGVENT ANCIEMENTATION		A or equivalent evidence of ity		□Yes □No □N/A				
attached to this form?	Agree	eements to enable transfer of erial eg MTA, SLA		□Yes □No	⊠N/A			
If No, add reference or details to ensure traceability	Detail	onsent og mmy betalls/evidence/assurance of onsent		□Yes □No	□n/a	*		

	Other (describe)		□Yes □No □N/A				
Temporary storage - Quarantine location (as applicable)	Building/Room		B7 R3 BxA (1)				
	Storage Unit ID		e		42		
	Within storage unit location ID						
д ррика, с,	Date/Time of quarantine		1	3 a			
Submitted by:	Signature:	J. ALT.	Date: 26	141	18		
PART C: To be completed by the	departmental Qu	ality Manager	dispersion to the		A THE RESERVE		
C1. Quality Assurance Checks							
Has the sample/specimen been so	☐Yes ☐No ☐N/A						
Has the donor been screened for infectious biological agents?					□Yes □No □N/A		
Has the sample/specimen been so	□Yes □No □N/A						
Is there evidence that the supplier/provider operates under national or international standards or other recognised certification?				□Yes □No □N/A			
For HTA licensable material, is there sufficient evidence to support the requirements for storage and use of the material under the University's HTA Research Licence?				□Yes □No □N/A			
Is there sufficient evidence to sup			ing exemption?	□Yes	□No □N/A		
C2. Approval for release from qu	arantine						
Can the material be released fron released for processing?	n quarantine and	transferred to desig	nated storage area or	□Yes	□No		
		☐Accept as is, but with extra controls					
		☐Rework or repressive specified requiren		•8	a a		
If No, provide recommendations of the material and the results of	any action	☐Test to meet specified requirements			v.		
relating to non-conforming mate	,	☐Return to supplier/provider		20			
		□Disposal		9	* v		
If Yes, provide details of storage lapplicable)	ocation (as	Building/Room			SPE		
		Storage Unit ID		r "			
		Within storage un	ge unit location ID		R3 DXA(1)		
		Database Reference			6 8		
		Date/Time of transfer			9 <u> </u>		
Approved by:		Signature:		Date:	1/5/18		